Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013 (2013), Article ID 793927, 6 pages
http://dx.doi.org/10.1155/2013/793927
Case Report

PET/MRI Imaging in High-Risk Sarcoma: First Findings and Solving Clinical Problems

1Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University at Dresden, Fetscherstraße 74, 01307 Dresden, Germany
2Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University at Dresden, 01307 Dresden, Germany
3Department of Radiology, University Hospital Carl Gustav Carus, Technical University at Dresden, 01307 Dresden, Germany
4PET Center, Institute of Radiopharmacy, Helmholtz-Zentrum Dresden-Rossendorf, 01328 Dresden, Germany
5Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, 13125 Berlin, Germany

Received 24 May 2013; Accepted 12 June 2013

Academic Editors: S. B. Chichareon, G. P. Vandoros, Y. Yokoyama, and N. Yoshimura

Copyright © 2013 Markus K. Schuler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Buchbender, T. A. Heusner, T. C. Lauenstein, A. Bockisch, and G. Antoch, “Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma,” Journal of Nuclear Medicine, vol. 53, pp. 1244–1252, 2012. View at Google Scholar
  2. M. H. M. Schwarzbach, A. Dimitrakopoulou-Strauss, F. Willeke et al., “Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas,” Annals of Surgery, vol. 231, no. 3, pp. 380–386, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. J. D. Lucas, M. J. O'Doherty, J. C. H. Wong et al., “Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas,” Journal of Bone and Joint Surgery. British, vol. 80, no. 3, pp. 441–447, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Hicks, G. C. Toner, and P. F. M. Choong, “Clinical applications of molecular imaging in sarcoma evaluation,” Cancer Imaging, vol. 5, no. 1, pp. 66–72, 2005. View at Google Scholar · View at Scopus
  5. M. R. Benz, N. Tchekmedyian, F. C. Eilber, N. Federman, J. Czernin, and W. D. Tap, “Utilization of positron emission tomography in the management of patients with sarcoma,” Current Opinion in Oncology, vol. 21, no. 4, pp. 345–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. R. Benz, J. Czernin, M. S. Allen-Auerbach et al., “FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas,” Clinical Cancer Research, vol. 15, no. 8, pp. 2856–2863, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. U. Tateishi, A. Kawai, H. Chuman et al., “PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study,” Clinical Nuclear Medicine, vol. 36, no. 7, pp. 526–532, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. L. Folpe, R. H. Lyles, J. T. Sprouse, E. U. Conrad III, and J. F. Eary, “(F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma,” Clinical Cancer Research, vol. 6, no. 4, pp. 1279–1287, 2000. View at Google Scholar · View at Scopus
  9. H. Jalal, Z. Belhadj, H. Enneddam et al., “Contribution of magnetic resonance imaging in the diagnosis of talus skip metastases of Ewing's sarcoma of the calcaneus in a child: a case report,” Journal of Medical Case Reports, vol. 5, article 451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. H. M. Schwarzbach, U. Hinz, A. Dimitrakopoulou-Strauss et al., “Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas,” Annals of Surgery, vol. 241, no. 2, pp. 286–294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. W. B. Arush, O. Israel, S. Postovsky et al., “Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma,” Pediatric Blood and Cancer, vol. 49, no. 7, pp. 901–905, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Völker, T. Denecke, I. Steffen et al., “Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial,” Journal of Clinical Oncology, vol. 25, no. 34, pp. 5435–5441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. S. Kneisl, J. C. Patt, J. C. Johnson, and J. H. Zuger, “Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas?” Clinical Orthopaedics and Related Research, no. 450, pp. 101–104, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Schuetze, B. P. Rubin, C. Vernon et al., “Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy,” Cancer, vol. 103, no. 2, pp. 339–348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Evilevitch, W. A. Weber, W. D. Tap et al., “Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas,” Clinical Cancer Research, vol. 14, no. 3, pp. 715–720, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Roberge, M. Hickeson, M. Charest, and R. E. Turcotte, “Initial McGill experience with fluorodeoxyglucose PET/CT staging of soft-tissue sarcoma,” Current Oncology, vol. 17, no. 6, pp. 18–22, 2010. View at Google Scholar · View at Scopus
  17. M. R. Benz, J. Czernin, M. S. Allen-Auerbach et al., “3-deoxy-3-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response,” Cancer, pp. 3135–3144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Herrmann, M. R. Benz, J. Czernin et al., “18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy,” Clinical Cancer Research, vol. 18, no. 7, pp. 2024–2031, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. H. Schwab, P. J. Boland, C. Antonescu, M. H. Bilsky, and J. H. Healey, “Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging,” Cancer, vol. 110, no. 8, pp. 1815–1822, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Frustaci, F. Gherlinzoni, A. De Paoli et al., “Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the italian randomized cooperative trial,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1238–1247, 2001. View at Google Scholar · View at Scopus
  21. E. Gortzak, A. Azzarelli, J. Buesa et al., “A randomised phase II study on neo-adjuvant chemotherapy for “high-risk” adult soft-tissue sarcoma,” European Journal of Cancer, vol. 37, pp. 1096–1103, 2001. View at Google Scholar
  22. P. J. Woll, M. van Glabbeke, P. Hohenberger et al., “Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial,” Journal of Clinical Oncology, vol. 18S, 2007. View at Google Scholar
  23. N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer, A. Figueredo, and M. Ghert, “A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma,” Cancer, vol. 113, no. 3, pp. 573–581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. Sarcoma Meta-analysis Collaboration (SMAC), “Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD001419, 2000. View at Publisher · View at Google Scholar
  25. J.-Y. Blay and A. Le Cesne, “Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven,” Oncologist, vol. 14, no. 10, pp. 1013–1020, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. Schuetze and S. Patel, “Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?” Oncologist, vol. 14, no. 10, pp. 1003–1012, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. P. G. Casali and J.-Y. Blay, “Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, no. 5, pp. v198–v203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Italiano, F. Delva, S. Mathoulin-Pelissier et al., “Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database,” Annals of Oncology, vol. 21, no. 12, pp. 2436–2441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Brenner, J. F. Eary, W. Hwang, C. Vernon, and E. U. Conrad, “Risk assessment in liposarcoma patients based on FDG PET imaging,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 11, pp. 1290–1295, 2006. View at Publisher · View at Google Scholar · View at Scopus